Description
Anti-LINGO-2 Antibody, Non-Fucosylated (BioBet-1183ZP) is a human monoclonal IgG antibody against LINGO-2. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Amylotrophic Lateral Sclerosis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced LINGO-2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
LINGO2
Full Name
leucine rich repeat and Ig domain containing 2
Alternative Names
LINGO2; leucine rich repeat and Ig domain containing 2; LERN3; LRRN6C; leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 2; leucine rich repeat neuronal 6C; leucine-rich repeat neuronal protein 3; leucine-rich repeat neuronal protein 6C
Gene ID
158038
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with LINGO2 include Tremor, Hereditary Essential, 3 and Tremor, Hereditary Essential, 5.
Post-translational modifications
1.Glycosylation at Asn38, Asn130, Asn188, Asn279, and Asn327 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1183ZP
Description
The anti-Lingo2 antibody are used for treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis.
Antibody Indication
Amylotrophic Lateral Sclerosis
Amylotrophic Lateral Sclerosis
